Scancell appoints Non-Executive Chairman of the Board

Scancell Holdings, a developer of novel immunotherapies for the treatment of cancer and infectious disease, has appointed Dr Jean-Michel Cosséry, as Non-Executive Chairman of the Board of Directors with immediate effect.

As previously announced, Dr John Chiplin - who has served as Chairman since 2016 - will step down following Cosséry’s appointment.

Cosséry will seek to drive Scancell’s strategy for clinical progress and commercial development of its novel immunotherapy vaccine and antibody platforms. He brings more than 25 years of experience in the pharmaceutical and biotechnology industries and a sustained global track record of success in commercial operations as well as in capital raising, US and European public offerings, business development and M&A.

Cosséry was Vice President for North America Oncology at Eli Lilly, with responsibility for commercialisation of the company’s oncology portfolio. Preceding this US-based position, he was Vice President and Managing Director of the Eli Lilly’s European Northern Hub, where he was Chair of the Eli Lilly UK Board and a member of Lilly European Executive Committee. Prior to this Jean-Michel served as VP and Chief Marketing Officer at GE Healthcare’s Global Headquarters.

Following his retirement from Eli Lilly in 2018, Cosséry served on the board of Kymab until their acquisition by Sanofi. He was also a member of the Immunocore board prior to the company’s Nasdaq listing. He currently serves on the boards of Malin PLC, Exact Therapeutics AS, Eracal Therapeutics and Sophia Genetics SA. He has also been Chair of The American Pharmaceutical Group in the UK, as well as a board member of the Association of British Pharmaceutical Industry.

Cosséry holds an MBA from the Rotterdam School of Management (Erasmus University), The Netherlands, as well as a PharmD and a PhD in Nuclear Chemistry and Neurobiology from University Paris, France.